Financial News · Live Terminal

Page 665 of 680

BofA Securities Adjusts Marsh & McLennan Price Target to $174 From $181, Maintains Underperform Rating

Marsh & McLennan (MRSH) has an average rating of Hold and mean price target of $203.62, according to analysts polled by FactSet.Price: $173.23, Change: $-0.33, Percent Change: -0.19%

$MRSH

Wire160d ago

BofA Securities Cuts Principal Financial Price Target to $92 From $96, Maintains Neutral Rating

Principal Financial Group (PFG) has an average rating of Hold and mean price target of $93.83, according to analysts polled by FactSet.Price: $93.91, Change: $+0.36, Percent Change: +0.38%

$PFG

Wire160d ago

BofA Securities Adjusts Neptune Insurance Price Target to $26 From $23, Maintains Neutral Rating

Neptune Insurance (NP) has an average rating of overweight and mean price target of $27.29, according to analysts polled by FactSet.Price: $25.96, Change: $+0.40, Percent Change: +1.56%

$NP

Wire160d ago

Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says

Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.Analysts said they are "positive" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.RBC has an outperform rating on the stock. It increased the price target to $53 from $49.Price: $31.24, Change: $-1.58, Percent Change: -4.81%

$IDYA

Wire160d ago

Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says

Charles River Laboratories International's (CRL) is positioned as the "leading" contract research organization, or CRO, for the acceleration of preclinical research and development into 2027, RBC Capital Markets said in a Monday note.RBC said improving macro conditions appear to be setting up an inflection in research and development spending, potentially starting in H2 and then accelerating through 2027. This expected increase in spending should benefit drive outsourcing to CROs and benefit Charles River Laboratories, the brokerage noted.Charles River Laboratories could also see an opportunity in the ongoing evolution of new alternative methods or NAMs, depending on the company's adoption of NAMS, RBC said.RBC initiated coverage on Charles River Laboratories International with an outperform rating and $215 price target.Price: $181.87, Change: $+3.53, Percent Change: +1.98%

$CRL

Wire160d ago

Stryker's Q1 Results to See Material Impact From March Cybersecurity Incident, RBC Says

Stryker (SYK) is expected to see a financial impact to its Q1 results, when the company reports its quarterly results on May 1, owing to a cybersecurity incident that had a material impact on its operations, RBC Capital Markets said in a research note.RBC lowered its Q1 estimates on the company, expecting adjusted diluted earnings per share of $2.86 and revenue of $6.23 billion, and said on Monday that the cyberattack appears to have primarily disrupted Stryker's internal business systems rather than its product portfolio.RBC said it was encouraged with the company's belief that the cyberattack will probably not have a material impact on the company's 2026 guidance of 8% to 9.5% organic revenue growth, but added that any upside potential to this outlook is now "likely limited," and it remains unclear if lost sales will return later in the year.The bank maintained its outperform rating on Stryker with a $435 price target and said that it continues to see the company as "among the highest-quality, defensive names in its MedTech coverage delivering durable growth."Price: $351.43, Change: $+4.19, Percent Change: +1.21%

$SYK

Wire160d ago

BofA Securities Lowers Goosehead Insurance Price Target to $37 From $43, Maintains Underperform Rating

Goosehead Insurance (GSHD) has an average rating of overweight and mean price target of $69.69, according to analysts polled by FactSet.Price: $41.86, Change: $-0.03, Percent Change: -0.07%

$GSHD

Wire160d ago

BofA Securities Adjusts Everest Group Price Target to $454 From $430, Maintains Buy Rating

Everest Group (EG) has an average rating of hold and mean price target of $361.19, according to analysts polled by FactSet.Price: $335.73, Change: $+2.30, Percent Change: +0.69%

$EG

Wire160d ago

Mizuho Securities Cuts Price Target on Allstate to $260 From $265, Maintains Outperform Rating

Allstate (ALL) has an average rating of overweight and mean price target of $243.25, according to analysts polled by FactSet.Price: $214.81, Change: $-0.28, Percent Change: -0.13%

$ALL

Wire160d ago

BofA Securities Adjusts Hartford Insurance Group PT to $138 From $136, Maintains Neutral Rating

Hartford Insurance Group (HIG) has an average rating of overweight and mean price target of $150.62, according to analysts polled by FactSet.Price: $139.02, Change: $-0.05, Percent Change: -0.04%

$HIG

Wire160d ago

BofA Securities Adjusts Lincoln National Price Target to $37 From $41, Maintains Neutral Rating

Lincoln National (LNC) has an average rating of Hold and mean price target of $42.58, according to analysts polled by FactSet.Price: $35.24, Change: $+0.33, Percent Change: +0.95%

$LNC

Wire160d ago

Mizuho Adjusts Price Target on Hartford Insurance Group to $158 From $160, Maintains Outperform Rating

Hartford Insurance Group (HIG) has an average rating of overweight and mean price target of $150.62, according to analysts polled by FactSet.Price: $139.02, Change: $-0.05, Percent Change: -0.04%

$HIG

Wire160d ago

Mizuho Adjusts Price Target on W. R. Berkley to $66 From $67, Maintains Neutral Rating

W. R. Berkley (WRB) has an average rating of hold and mean price target of $67.69, according to analysts polled by FactSet.Price: $66.40, Change: $-0.56, Percent Change: -0.84%

$WRB

Wire160d ago

Mizuho Adjusts Price Target on Progressive to $217 From $223, Maintains Neutral Rating

Progressive (PGR) has an average rating of overweight and mean price target of $231.81, according to analysts polled by FactSet.Price: $198.18, Change: $-1.39, Percent Change: -0.70%

$PGR

Wire160d ago

Mizuho Adjusts Price Target on Travelers to $305 From $304, Maintains Neutral Rating

Travelers (TRV) has an average rating of hold and mean price target of $309.83, according to analysts polled by FactSet.Price: $300.87, Change: $-0.44, Percent Change: -0.15%

$TRV

Wire160d ago

International Business Machines Likely to Post Q1 Beat, Morgan Stanley Says

International Business Machines' (IBM) Q1 earnings are likely to move higher, but unlikely to reignite the bull case as the quarterly beat won't boost full-year earnings or free cash flow guidance, Morgan Stanley said in a Tuesday research report.The company could post a Q1 beat as channel checks indicate year-over-year software growth during the quarter, while consulting jobs postings tracker gained 14% sequentially, according to the note.Morgan Stanley revises Q1 EPS estimate to $1.91 from $1.83 earlier on revenue of $16.2 billion from $15.8 billion. For Q2, it expects EPS of $3.03 on revenue of $17.9 billion, analysts wrote.Artificial intelligence disruption risk exists at IBM, concentrated in data and automation, making it crucial that IBM shows full year estimate upside to overcome valuation pressure, according to the brokerage.IBM is scheduled to report Q1 financial results on April 22.The brokerage said it reiterated its equalweight rating on the stock and cut its price target to $215 per share from $247.Price: $240.69, Change: $+2.87, Percent Change: +1.20%

$IBM

Wire160d ago

ASML Likely to Report Slight Beat in Q1, RBC Says

ASML (ASML) is expected to deliver a slight beat in Q1 and to sustain double-digit revenue momentum for the next two to three years on GenAI demand, RBC Capital Markets said in a Monday report. The results are due April 15.RBC analysts said they are modeling revenue of 8.7 billion euros ($10.3 billion) and EPS of 6.59 euros for the quarter, largely in line with market consensus."Tight DRAM supply, growing EUV intensity, and re-emergence ofadvanced Foundry competition are the other key tailwinds," the note said. EUV refers to extreme ultraviolet lithography systems.The report said wafer fab equipment demand has further strengthened in recent months, driven by tightness in Dynamic random-access memory and strong 3-nanometer wafer demand.While clean room is a bottleneck, the report said China is largely de-risked and offers near-term upside potential.RBC kept its outperform rating and a $1,625 price target.Price: $1516.47, Change: $+16.27, Percent Change: +1.08%

$ASML

Wire160d ago

BofA Securities Cuts Corebridge Financial Price Target to $40 From $42, Maintains Buy Rating

Corebridge Financial (CRBG) has an average rating of overweight and mean price target of $35.31, according to analysts polled by FactSet.Price: $25.41, Change: $+0.47, Percent Change: +1.88%

$CRBG

Wire160d ago

Mizuho Adjusts Price Target on Chubb to $335 From $336, Maintains Neutral Rating

Chubb (CB) has an average rating of overweight and mean price target of $344.26, according to analysts polled by FactSet.Price: $327.45, Change: $-2.53, Percent Change: -0.77%

$CB

Wire160d ago

BofA Securities Trims Cincinnati Financial Price Target to $177 From $178, Maintains Buy Rating

Cincinnati Financial (CINF) has an average rating of overweight and mean price target of $173.33, according to analysts polled by FactSet.Price: $163.56, Change: $-0.12, Percent Change: -0.07%

$CINF

Showing 13281-13300 of 13586